Navigation Links
Scientists uncover image of muscular dystrophy defect & design targeted drug candidates
Date:1/2/2014

JUPITER, FL, January 2, 2013 Scientists from the Florida campus of The Scripps Research Institute have revealed an atomic-level view of a genetic defect that causes a form of muscular dystrophy, myotonic dystrophy type 2, and have used this information to design drug candidates with potential to counter those defectsand reverse the disease.

"This the first time the structure of the RNA defect that causes this disease has been determined," said TSRI Associate Professor Matthew Disney, who led the study. "Based on these results, we designed compounds that, even in small amounts, significantly improve disease-associated defects in treated cells."

Myotonic dystrophy type 2 is a relatively rare form of muscular dystrophy that is somewhat milder than myotonic dystrophy type 1, the most common adult-onset form of the disease.

Both types of myotonic dystrophy are inherited disorders that involve progressive muscle wasting and weakness, and both are caused by a type of genetic defect known as a "RNA repeat expansion," a series of nucleotides repeated more times than normal in an individual's genetic code. The repeat binds to the protein MBNL1, rendering it inactive and resulting in RNA splicing abnormalitieswhich lead to the disease.

Many other researchers had tried to find the atomic-level structure of the myotonic dystrophy 2 repeat, but had run into technical difficulties. In a technique called X-ray crystallography, which is used to find detailed structural information, scientists manipulate a molecule so that a crystal forms. This crystal is then placed in a beam of X-rays, which diffract when they strike the atoms in the crystal. Based on the pattern of diffraction, scientists can then reconstruct the shape of the original molecule.

Prior to the new research, which was published in an advance, online issue of the journal ACS Chemical Biology, scientists had not been able to crystallize the problematic RNA. The Scripps Florida team spent several years on the problem and succeeded in engineering the RNA to have crystal contacts in different positions. This allowed the RNA to be crystallizedand its structure to be revealed.

Using information about the RNA's structure and movement, the scientists were able to design molecules to improve RNA function.

The new findings were confirmed using sophisticated computational models that show precisely how the small molecules interact with and alter the RNA structure over time. Those predictive models matched what the scientists found in the studythat these new compounds bind to the repeat structure in a predictable and easily reproducible way, attacking the cause of the disease.

"We used a bottom-up approach, by first understanding how the small components of the RNA structure interact with small molecules," said Jessica Childs-Disney of TSRI, who was first author of the paper with Ilyas Yildirim of Northwestern University. "The fact that our compounds improve the defects shows that our unconventional approach works."


'/>"/>

Contact: Eric Sauter
esauter@scripps.edu
267-337-3859
Scripps Research Institute
Source:Eurekalert  

Related biology news :

1. Scientists look to tackle bacterium that is major cause of diarrhea, vomiting
2. Study led by NUS scientists provides new insights into cause of human neurodegenerative disease
3. Scientists find a groovy way to influence specialization of stem cells
4. WSU scientists find burglary-ring-like mechanism in lethal Contagion virus
5. UCLA stem cell scientists first to track joint cartilage development in humans
6. Sniffing out danger: Rutgers scientists say fearful memories can trigger heightened sense of smell
7. Scientists map food security and self-provision of major cities
8. Scientists identified T372R mutation as potential target for diagnosis and treatment of insulinoma
9. Gene-silencing data now publicly available to help scientists better understand disease
10. Eurofins scientists discover genetic differences between identical twins
11. Oregon scientists offer new insights on controlling nanoparticle stability
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scientists uncover image of muscular dystrophy defect & design targeted drug candidates
(Date:6/20/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring announced that after exhaustive ... the final acceptance by all three (3) Department ... (MAS) installed. Furthermore, Securus will have contracts for ... October, 2016. MAS distinguishes between legitimate wireless device ...
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/1/2016)... 1, 2016 Favorable Government Initiatives ... and Criminal Identification to Boost Global Biometrics System Market ... TechSci Research report, " Global Biometrics Market By ... and Opportunities, 2011 - 2021", the global biometrics market ... on account of growing security concerns across various end ...
Breaking Biology News(10 mins):
(Date:11/30/2016)... SAN DIEGO and BEIJING ... Ltd., a leading commercial provider of genomic services and ... expertise, announced today that it has completed a USD ... China Merchants Bank Co., Ltd.,s CMB International Capital Management ... SDIC Innovation Investment Management Co., Ltd. ("SDIC Innovation") and ...
(Date:11/30/2016)... Mass. , Nov. 30, 2016   Merck ... that it has entered into a set of agreements ... services for Merck,s collection of genetic reagents such as ... with Evotec,s screening expertise offers an accelerated pathway to ... discovery starts with the identification of new targets, a ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... development of a new orally administered treatment for Alzheimer’s disease (AD), today announced ... a Phase 2a clinical trial of T3D-959 in mild to moderate Alzheimer’s patients ...
(Date:11/30/2016)... ... November 30, 2016 , ... ProMIS Neurosciences (“ProMIS” or the ... diseases, today announced that all five of its validated monoclonal antibody (mAb) therapeutic ... toxic, prion-like forms of Amyloid beta (Aß) in vitro. , “We previously demonstrated ...
Breaking Biology Technology: